EBM 2/2018 Summer Free Excerpt

ISSN 2364-2351 | A 60711 |

Life Sciences and Industry Magazine Summer Edition 2018 | Volume 17 | 20 €

Haemophilia A

Interview Novartis CEO Vasant Narasimhan reveals why he bets on one-time curative treatments and digital tools

T P R E E EXC

FRE

Fixing the leak Nanobots

Agrochemistry

Bioeconomy

Biofairs Compass

Microscopic drug delivery systems – the next big thing

Bayer-Monsanto to bet on genome editing in crop design

Global policy leaders lay out agenda to push biologisation

The ultimate guide to leading Life Sciences Events in H2/2018

Don´t prepare. Just be ready.

C2MAP-2000 – 1 method, 17 mins, 95 media components The new C2MAP-2000 automates all steps from pretreatment to measurement without any human intervention. It simplifies the workflow for optimizing cell culture conditions. There is no need to prepare. Just be ready.

Complete LCMS solution for cell culture analysis combining the C2MAP-2000 pretreatment module with ultra-fast LCMS-8060

Monitoring of up to 95 components including amino acids, metabolites, sugars, vitamins and organic acids Changes at a glance with C2MAP-TRENDS viewer software visualizing temporal changes of components

Highly efficient through cutting culture media analysis time by 80 percent

www.shimadzu.eu/c2map

C2MAP-2000 – Complete LCMS solution

European Biotechnology | Summer Edition | Vol. 17 | 2018

Intro FREE EXCERPT

Single-use plastics: New EU rules to reduce marine litter Plastics are magical materials, and they will be even more important in the future than they are today. But they lead to microplastics in the environment, especially noticeable as “marine littering.”

The European Commission is now proposing, among other things, a ban on certain single-use plastic products, including “plastic cotton buds, cutlery, plates, straws, drink stirrers, and sticks for balloons, which will all have to be made exclusively from more sustainable materials instead.” The Commission’s legislative proposal must then be negotiated with the member states and the European Parliament.

And here substantial changes should still be made – because so far industry and politics continued to fail in this area.

Michael Carus The founder and Managing Director of the nova-Institute studied physics and mathematics at the University of Cologne. Carus became a lecturer at the University of Tübingen, on the topics of ecology, nuclear energy, and radioactivity. He worked as a science journalist and scientist at the KATALYSE Environmental Institute with a focus on energy, ecology, and renewable resources, and two years in the solar industry. In 1994, he founded the nova-Institute for Ecology and Innovation.

Microplastics have been in the public eye for at least ten years.

The plastics industry has waited until the public pressure became too high to ignore. Then their argument was, what can our plastics do if people do not handle our products properly and politicians do not organise better recycling programmes?

But in fact, the plastics industry can do something about it. For years, there has been another solution for plastic products that are practically impossible to recycle or whose preparation is far too costly: biodegradable plastics.

The European Commission has spent several million Euros over the last ten years to develop and certify such plastics. Plastics that are biodegradable in water, soil, home compost or industrial composting and do not leave any microparticles behind.

And today there are many producers of biodegradable plastics; there are certifications and labels. But these new plastics are still a little too expensive to become sure-fire success. And now they don’t even get a chance in the new European plastics strategy!

Picture: Nova Institute, Cologne

Seize the opportunity for innovation and sustainability now. We prohibit single-use products if they are not biodegradable. But let us give biodegradable plastics, which have been successfully developed for years, their chance on the market! We also need alternatives to plastic products that, even when used properly, end up in the environment and are difficult or impossible to recycle. A few examples would be mulch films, tree protection covers, plant clips, binding yarns, strings for lawn trimmers, carrier polymers for fertilizers and pesticides, and even plastic baits at sea. Let us take a step forward in all of Europe. Because now is the time when the rules for the coming decades are being made.

Further reading: http://bio-based.eu/policy/#innprobiofacts

3

Contents

European Biotechnology | Summer Edition | Vol. 17 | 2018

FREE EXCERPT

Cover Story

Insight Europe

regional news

6 User-driven early certainty: EPO steps back

66 Northern Europe: Sweden, Denmark, Norway and Finland

10 Launch of European PNAS; More rights for European CDMOs 11 European Commission proposes €100m budget for Horizon Europe

Economy 17 Interview (Haemophilia): Gallia Levy, Global Development Team Leader, Hemlibra, Roche AG

68 Western Europe:

France, Belgium, The Netherlands

and the UK

70 Central Europe:

Germany, Switzerland

and Austria 72 Southern Europe: Italy, Spain, Greece, Slovenia, and Greece

19 Update on clinical trials 22 Interview (Strategy):

Vas Narasimhan, CEO, Novartis AG

12

Stopping the bleed Since factor VIII replacement therapies hit the market, life expectancy for haemo­ philia patients has risen to normal levels.

But around 25% of those who suffer from haemophilia A still have no therapeutic options, because their immune systems form antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US$15bn haemo­philia medications market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments, while a series of mergers and acquisitions have changed the playing field for established markets and players.

24 EMA News

74 Eastern Europe:

Poland, Czech Republic and

Hungary

Science & Technology

25 Analyst commentary 26 Euro Biotech Stocks

80 F irst mesenchymal stem cell therapy hits the European market

28 Interview (Bioeconomy Finance): Rob Carlson, Managing Director, Bioeconomy Capital

82 Approved diabetes medicine helps PAH patients

30 Headwinds in sustainable industry

and manufacturing

Service

33 Falsified medicines deadline nears 34 Interview; Hannes Teissl, Polpharma Biologics 36 Interview: Federico Pollano, Rentschler Biopharma

75 Biopeople 84 News from partner associations: Swiss Biotech Association, Medtec Europe and Europa­Bio 88 Events 89 Company index/New products 90 Encore

IMPRINT European Biotechnology (ISSN 2364-2351) is published quarterly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, Email: service@european-biotechnology.com, Internet: www.european-biotechnology.com; Publisher: Andreas Mietzsch; Editorial Team: Thomas Gabrielczyk (Editor in Chief), Derrick Williams (Coeditor), Dr. Martin Laqua, Helene Märzhäuser, Sandra Wirsching; Advertising: Oliver Schnell, +49-30-2649-2145, Christian Böhm, +49-30-2649-2149, Andreas Macht, +49-30-2649-2154; Distribution: Marcus Laschke, +49-30-2649-2148; Graphic Design: Oliver-Sven Reblin; Production editor: Benjamin Röbig; Printed at: Königsdruck, Berlin; European Biotechnology Life Sciences & Industry Magazine is only regularly available through subscription at BIOCOM AG. Annual subscription fees: € 80.00, Students € 40.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within two weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least six weeks before the date of expiry. Failures of delivery, which BIOCOM AG is not responsible for, do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Cover Photo: Naeblys/istockphoto.com; Supplement: ASEBIO, EFIB/BIOCOM; ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

Picture: Naeblys/istockphoto.com

4

Contents

European Biotechnology | Summer Edition | Vol. 17 | 2018

FREE EXCERPT

Drug Delivery

Agri-biotech

Editorial

Consolidation up top

Global discharge

They co-created Agent Orange. Now agri-biotech giants Bayer and Monsanto are about to merge into a single mega­ entity for pushing genetic engineering technologies in the crop design market.

European Biotechnology takes a look at what consumers and farmers can expect, and how new products will be regulated in the age of the ‘Big Four’.

60

Nanobot healthcare They’re small, fast – and could be the future of medicine. Nanobots have already been used in animal trials to attack tumours, and have proven effective. But there are still a few problems to overcome before doctors begin injecting millions of tiny machines into humans. Not least that researchers still have to figure out how to get rid of the microscopic helpers once they’ve done their job.

76

Pictures: iordani/fotolia.com (top), loneroc/shutterstock.com (middle), ABLinc. (bottom)

SPECIAL Event compass 39 Intro: update on EU events 40 NLS Days, Stockholm 42 European Biotech Week 44 Biospain, Seville

46 bioLIVE, Madrid

48 BIO Japan, Yokohama 50 EFIB, Toulouse

52 European Business Development

Conference, Hanover, Germany 54 BIO Europe, Copenhagen 56 Pharmalab, Düsseldorf

58 Biofit, Lille

At the recent Global Bioeconomy Summit (see. p. 30), US researcher John Schramski had an interesting message. He sees our planet as an accumulator that’s been charged up by hundreds of millions of years of photosynthesis. Until now, he said, Earth has been able to effortlessly top up reserves. But as energy consumption by humans exploded over the past century, its currency of biomass and fossil fuel has been almost fully depleted. “We have to slow down,“ Schramski warns – because without our natural resources we won’t survive.

An interesting aspect of the international meeting was that two major lobbies were apparent. There were those who pushed the idea that we all need to focus on sustainability, because no one knows how much longer we can go on exploiting our planet (see p. 32). On the other side were those who primarily see the economic opportunities attached to green technology (see p. 28).

Maybe biologisation of the industry is about both. Making money, but with the right biotechnologies for rebalancing economic, social and ecological imbalances.

The challenge now is to separate those who tout old technology to make money under green labels from those offering the right solutions.

Thomas Gabrielczyk Editor-in-Chief

5

Rubrik

European Biotechnology | Winter Edition | Vol. 16 | 2017

Pictures: xxx

12

HAematology

European Biotechnology | Summer Edition | Vol. 17 | 2018

FREE EXCERPT

Closing the gap in haemophilia therapy Factor VIII inhibitors About 25% of the people who suffer from haemophilia A have no

therapeutic options, because their immune system forms antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US$15.8bn haemophilia market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments. A series of mergers and acquisitions have changed the playing field for established markets and players.

Pictures: PEI (right), selvanegra/istockphoto.com (left)

E

very time Michael fell when he was a child, his parents had to rush him to the hospital. “Between the ages of one and six, we were there pretty much every day,” his mother remembers. Her son is one of 320,000 people worldwide with haemophilia A, the more common form of the genetic condition. People living with the hereditary disease either don’t produce enough of a clotting protein called factor VIII, or they lack it completely. Because their blood doesn’t clot properly, it can lead to uncontrolled bleeding. The disease is called ‘mild’ when FVIII levels are 5%-40% of normal levels, ‘moderate’ when between 1%-5%, and ‘severe’ when they’re under 1%. Michael has the severe form. Injections with factor VIII, the current standard of care, can prevent and treat bleeding episodes. “I try to do what I can, and not spend too much time thinking about what I can’t do,” says Michael, now a young man. “For me, that’s a kind of motto in life.” Starting in the 1950s, prophylactic factor VIII infusions were derived to treat haemophiliacs with plasma-derived factor VIII products from donors. In the 1990s, complement­ary treatments with recombinant factor VIII proteins hit the scene. Prophylactic factor VIII replacement therapy has now cut the average number of bleeds from more than 40 a year to under two. Today, a child born with severe haemophilia can expect to have a normal lifespan. But besides annual treatment costs of US$150,000-$300,000 per

patient, other serious hurdles remain.

Prophylactic therapy patients continue to need drugs that will decrease their need for immuno­suppressants. The half-life of the active factor VIII protein is also short, and needs to be extended. And most importantly, a significant number of patients simply don’t respond to treatment.

Almost one in three people with severe haemophilia A also develops inhibitors –

Zoe Waibler Head Product Assessor for Immunologic Drugs, Paul Ehrlich Institute, Langen (Germany)

? !

hy is it important to find factors W in the blood that boost factor VIII inhibitor formation?

It’s a prerequisite for developing new approaches to haemophilia therapies, which prevent the formation of these inhibitors against factor-VIII products.

antibodies that identify the recombinant blood clotting factor VIII as foreign, and stop it from working. For the big players in the currently US$15.8bn field – Shire, Biogen/Bioverativ, Novo Nordisk, Pfizer and others (see table, p. 14) – new approaches to solving those problems could have a big impact on revenues. The market is growing. Analysts from Transparency Market Research predict it will surpass US$25bn by 2024.

The huge unmet medical need and associated potential has triggered major acquisitions, with former market leaders under new ownership. Biogen­haemophilia spinout Bioverativ, for instance, was taken over by Sanofi for US$11.8bn. In a US$62bn acquisition, haemophilia amd haematology giant Shire plc agreed in May to a takeover by Takeda. Approaches for circumventing the immuno­genicity and inhibitor problem – such as factor VIII products with fully human glycosylation patterns, gene therapies or bi­specific antibodies that mimic the effects of factor VIII with less or no potential for inhibitor formation – have the potential to change the field dramatically.

Predicting inhibitor formation However, current claims involving reduced immunogenicity and reduced […]

›› Read the full story in the printed issue.

13

Drug Delivery

European Biotechnology | Summer Edition | Vol. 17 | 2018

FREE EXCERPT

Nanobots: Fiction becoming reality Drug Delivery Once confined to speculative and science fiction, miniature micro- or

nanobots targeting pathogens or conditions directly have now become reality in research labs worldwide. But to enter clinical trials, scientists still have to overcome two major hurdles – visualising the tiny machines inside the body, and preventing a potential immune response.

›› Read the full story in the printed issue.

Pictures: Biodesign Institute, Arizona State University

60

Agriculture

European Biotechnology | Summer Edition | Vol. 17 | 2018

FREE EXCERPT

A tractor entailing a fog of pesticides – a rare sight in a couple of years? Precision distribution of crop protecting agents via for instance drones could soon usher out mass spraying.

The future of agrochemistry Pesticides & Seeds One of the world’s largest and most controversial mergers in the past few

years was sealed in early June. German pharma and chemistry company Bayer has taken over US competitor Monsanto, forming the largest integrated provider of seeds, agrochemicals and digital farming solutions on the planet. The acquisition is part of a recent US$170bn deal binge that is already having a profound impact on the future of global agriculture.

›› Read the full story in the printed issue.

Picture: fotolia.de/ValentinValkov

76

European Biotechnology | Summer Edition | Vol. 17 | 2018

company index /Product FREE EXCERPT

3P Biopharmaceuticals S.L. (ES). . . . . . . . . . . . . . . . . . . . 67 Abcam (UK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 69 Ablynx (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Adama (IL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 78 ADC Therapeutics SAS (CH). . . . . . . . . . . . . . . . . . . . . . . 20 Affiris AG (AT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Aldevron GmbH (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . 75 Alexion Pharmaceuticals (USA) . . . . . . . . . . . . . . . . . . . . 67 Amgen Europe B.V. (CH). . . . . . . . . . . . . . . . . . . . . . . . . 24 Amplidiag Oy (FI). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Anergis SA (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 ASEBIO (ES). . . . . . . . . . . . . . . . . . . . . . . . . 45, Supplement Asit Biotech SA (B). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 AstraZeneca AB (SE/UK). . . . . . . . . . . . . . . . . . . . . . . . . . 19 Avexis Inc. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 71 BASF AG (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 78, 79 Bayer AG (DE) . . . . . . . . . . . . . . . . . . 19, 21, 25, 77, 78, 79 BIA Separations d.o.o. (SLO). . . . . . . . . . . . . . . . . . . . . . . 73 BIOCOM AG (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CP3 BioFIT 2018 (F). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Biogen Idec (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 71 Biognosys AG (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 BioJapan 2018 (JP). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 Biological Industries (BI) Ltd. (USA) . . . . . . . . . . . . . . . . . 83 Biomarin Pharmaceuticals (USA) . . . . . . . . . . . . . . . . . . . 16 Biomay AG (AT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 Bioverativ (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Biovertis AG (AT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68 bluebird bio (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 71 Boehringer Ingelheim (DE). . . . . . . . . . . . . . . . . . . . . . . . 69 CANDOR Bioscience GmbH (DE) . . . . . . . . . . . . . . . . . .

Capital Cell (ES). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Cara Therapeutics (USA). . . . . . . . . . . . . . . . . . . . . . . . . .

Cargill Inc. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Cassiopea SPA (IT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Celgene Corp. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . .

Cellectis (F). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ChemChina (CN) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Chugai Pharma Europe Ltd. (UK) . . . . . . . . . . . . . . . . . . .

Citoxlab Group (F). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Clovis Oncology UK Ltd.. . . . . . . . . . . . . . . . . . . . . . . . .

Coca-Cola (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Concept Heidelberg (DE). . . . . . . . . . . . . . . . . . . . . . . . .

Cosmo Pharmaceuticals NV (NL). . . . . . . . . . . . . . . . . . .

CPhI / BioLive 2018 (NL) . . . . . . . . . . . . . . . . . . . . . . . . .

CRISPR Therapeutics (CH/USA) . . . . . . . . . . . . . . . . . . . .

Cynata Ltd. (AU). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

23 73 70 79 70 71 25 77 17 74 24 10 57 21 47 20 82

Deinove SA (F). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

DGPharMed/DGPharmMed Annual Meeting 2019 (DE). .

DowDuPont (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Dunn Labortechnik GmbH (GER . . . . . . . . . . . . . . . . . . .

Dynabind GmbH (DE) . . . . . . . . . . . . . . . . . . . . . . . . . . .

68 38 77 11 74

EFIB 2018 (B). . . . . . . . . . . . . . . . . . . . . . . . 51, Supplement EBD Group (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 Eppendorf AG - Bioprocess Center Europe (DE) . . . . . . . . . 7 EuropaBio /European Biotech Week (EU). . . . . . . . . . . . . 43 European Business Dev. Conf. 2018 (DE). . . . . . . . . . . . . 53 Evotec AG (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Exelixis, Inc. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 FESIA (ES). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 FGK Clinical Research GmbH (DE). . . . . . . . . . . . . . . . . . 18 FMC Agricultural Solutions (USA). . . . . . . . . . . . . . . . 77, 78 Freenome Inc. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Genentech Inc. (USA). . . . . . . . . . . . . . . . . . . . . . 17, 20, 21 Genewave SAS (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Genmab A/S (DK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 GenSight Biologics (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Gilead Ltd. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 GlaxoSmithKline (UK) . . . . . . . . . . . . . . . . . . . . . . . . 25, 69

Kite Pharma (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Lundbeckfond Ventures (DK) . . . . . . . . . . . . . . . . . . . . . . 66 Medical Prognosis Institute A/S (DK). . . . . . . . . . . . . . . . . 66 MediGene AG (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 71 Merck & Co. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 25 Merck KGaA (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Mesoblast Ltd. (AU) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 Mobidiag Oy (FI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Molecular Partners AG (CH). . . . . . . . . . . . . . . . . . . . . . . 70 MolMed (IT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Mologen AG (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Monsanto (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 77, 78, 79 MorphoSys AG (DE). . . . . . . . . . . . . . . . . . . . . . . . . . 68, 71 Mymetics S.A. (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Nestle S.A. (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Neurimmune AG (CH). . . . . . . . . . . . . . . . . . . . . . . . 71, 75 NMD Pharma A/S (DK). . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Nordic Life Science Day (SE) 2018. . . . . . . . . . . . . . . . . . 41 nova-Institut GmbH (DE) . . . . . . . . . . . . . . . . . . . . . . . . . 29 Novartis AG (CH). . . . . . . . . . . . . . . . . . . . . . 22, 23, 71, 72 Novo Nordisk A/S (DK). . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Novo Seeds (DK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Novozymes A/S (DK) . . . . . . . . . . . . . . . . . . . . . . . . . 25, 31 NTC Pharma (IT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 Nufarm Ltd. (AU). . . . . . . . . . . . . . . . . . . . . . . . . . . . 78, 79 Oncoarendi Therapeutics SA (PL). . . . . . . . . . . . . . . . . . .

Oncology Venture Sweden AB (SE). . . . . . . . . . . . . . . . . .

OPIS s.r.l. (IT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Orchard Therapeutics (UK/USA). . . . . . . . . . . . . . . . . . . .

Ose Immunotherapeutics SA ( . . . . . . . . . . . . . . . . . . . . .

Osiris Therapeutics (USA). . . . . . . . . . . . . . . . . . . . . . . . .

Otsuka Pharmaceutical

74 66 19 69 69 82

Cancer research Promocell PromoKine’s Angiogenesis Assay Kit provides a simple, robust, easy to perform and semi-quantitative method to determine angiogenesis in vitro in less than 18 hours. It can be used for screening of angiogenesis modulators or studies of angiogenesis related signal transduction.

The assay is based on the measurement of the ability of endothelial cells to form 3D structures (tube formation) under the influence of distinct stimulators, and uses a proprietary endotoxin-free and growth factorreduced Extracellular Matrix Solution.

The Cell Migration/Chemotaxis Assay Kits are easy to use, sensitive and high throughput-adaptable systems. They uti-

PepsiCo. (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Pfizer (USA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 19 Polpharma Biologics (PL) . . . . . . . . . . . . . . . . . . 34, 35, CP4 Polyphor Ltd. (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Procter & Gamble (USA). . . . . . . . . . . . . . . . . . . . . . . . . . 25 Promocell GmbH (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . 89 Puretech Health plc (USA). . . . . . . . . . . . . . . . . . . . . . . . 75 Qiagen NV (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Reckitt Benckiser (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Redx Pharma (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . 68, 75 Regeneron Pharmaceuticals Inc. (USA). . . . . . . . . . . . 19, 21 Rentschler Biotechnologie GmbH (DE). . . . . . . . . . . . 36, 75 Roche Group (CH). . . . . . . . . . . . 15, 16, 17, 19, 21, 25, 71 Roche Venture Fund (CH). . . . . . . . . . . . . . . . . . . . . . . . . 66 Sangamo Biosciences Inc. (USA) . . . . . . . . . . . . . . . . . . . 16 Sanifit (ES) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 Sanofi SA (F) . . . . . . . . . . . . . . . . . . . . . . . . . 13, 21, 25, 75 Servier (F). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Shimadzu (DE). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CP2 Shire plc (IRL). . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 16, 69 Shuwen Biotech (CN). . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Siemens Healthineers (DE). . . . . . . . . . . . . . . . . . . . . . . . 25 Solvo Biotechnology sro (HUN). . . . . . . . . . . . . . . . . . . . 74 Sophia Genetics (CH). . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 Sotio a.s. (CZ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Springvest (FI). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Sunshine Kaidi Finland New Energy Co. Oy (CN/FIN) . . . 67 Syngenta AG (CH) . . . . . . . . . . . . . . . . . . . . . . . . 77, 78, 79 Takeda Pharma A/S (DK). . . . . . . . . . . . . . . . 13, 16, 69, 82 Targovax AS (NO). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Tech4Freedom (ES). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 Thrombogenics (B). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 TiGenix (B). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81, 82 Trianni, Inc. (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 TVM Capital Life Science (DE). . . . . . . . . . . . . . . . . . . 9, 68 uniQure BV (NL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

lize a Boyden chamber, where the cells migrate through a semi-permeable membrane (three different pore sizes available) in response to stimulatory or inhibitory compounds.

The Cell Invasion Assay Kits also utilize a Boyden chamber that is coated with a layer of BME (Basement Membrane Extract), laminin, fibronectin, Collagen I or Collagen IV. The cells first traverse the matrix and then migrate through the semi-permeable membrane in the Boyden chamber in response to different stimuli. Cell migration as well as cell invasion can be analysed directly using a fluorescence plate reader. D

Pictures: PromoCell

Horizon Discovery Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . 25 Idorsia (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

INKEF Capital (NL). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Intervac AB (SE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Ionis Pharmaceuticals (USA). . . . . . . . . . . . . . . . . . . . . . .

70 66 67 71

Janssen Biotech Inc. (USA). . . . . . . . . . . . . . . . . . . . . . . . 20 Jennewein Biotechnologie GmbH (DE). . . . . . . . . . . . . . . 20

Versli Lietuva (LT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vertex Pharmaceuticals Inc. (USA). . . . . . . . . . . . . . . . . .

Vetter Pharma-Fertigung GmbH & Co.KG. . . . . . . . . . . . .

Vifor Pharma AG (AT). . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vivet Therapeutics (F). . . . . . . . . . . . . . . . . . . . . . . . . . . .

35 20 21 70 67

Wilhelm Bähren GmbH & Co. KG (DE) . . . . . . . . . . . . . . 33 Wilson Therapeutics AB (SE). . . . . . . . . . . . . . . . . . . . . . . 67

Contact

PromoCell GmbH Sickingenstr 63/65, 69126 Heidelberg www.promokine.info info@promokine.info

89

14.|15.3.

2019 12 th Berlin Conference on Life Sciences

Novel Antimicrobials and AMR Diagnostics Save the date: On 14 and 15 March 2019, the Berlin Conference will once again be the meeting place for Life Science decision makers, business developers, investors and legal experts. The conference will explore the exciting market for the development of novel antimicrobials and AMR diagnostics.

Find more information at:

www.berlin-conferences.com

BIOCOM AG I Lützowstraße 33–36 I 10785 Berlin | Germany events@biocom.de I Tel. +49 (0)30 264921-53 I www.biocom.de

Drug substance and Fill&Finish BC®

Own CHO

platform

���� �������

���-����-���� ��� ������������������

mABs New AB formats Proteins ����� ����� ���������� �������������

��� ������������� (2000�) ����� ������������� ����������� (50-1000�)

www.polpharmabiologics.com

����������� �����������

onestopshop@polpharma.com

���-����� ������� ����������� ���

���-����� ������� ����������� ���

���������� �����������

���� ���� ����������� (����� ������)